Evercore Wealth Management LLC reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 1.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,486 shares of the medical instruments supplier’s stock after selling 104 shares during the period. Evercore Wealth Management LLC’s holdings in Becton, Dickinson and were worth $1,577,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in BDX. Solstein Capital LLC purchased a new stake in shares of Becton, Dickinson and during the 1st quarter valued at about $28,000. Sage Private Wealth Group LLC purchased a new stake in shares of Becton, Dickinson and during the 4th quarter valued at about $37,000. Fort Pitt Capital Group LLC purchased a new stake in shares of Becton, Dickinson and during the 4th quarter valued at about $38,000. Ameritas Investment Company LLC purchased a new stake in shares of Becton, Dickinson and during the 1st quarter valued at about $39,000. Finally, Mascoma Wealth Management LLC purchased a new stake in Becton, Dickinson and during the 1st quarter worth approximately $41,000. Institutional investors and hedge funds own 83.25% of the company’s stock.
In related news, Director Claire Fraser sold 390 shares of the business’s stock in a transaction that occurred on Thursday, May 27th. The stock was sold at an average price of $241.36, for a total transaction of $94,130.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.76% of the company’s stock.
Shares of NYSE BDX opened at $246.35 on Thursday. Becton, Dickinson and Company has a twelve month low of $219.50 and a twelve month high of $284.97. The company has a quick ratio of 1.32, a current ratio of 1.86 and a debt-to-equity ratio of 0.71. The company has a market cap of $71.64 billion, a P/E ratio of 43.83, a price-to-earnings-growth ratio of 2.19 and a beta of 0.76. The firm has a 50 day moving average price of $243.86.
Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Wednesday, May 5th. The medical instruments supplier reported $3.19 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.04 by $0.15. Becton, Dickinson and had a return on equity of 15.53% and a net margin of 8.98%. The business had revenue of $4.91 billion during the quarter, compared to analyst estimates of $4.88 billion. During the same quarter in the previous year, the firm posted $2.55 EPS. The business’s revenue for the quarter was up 15.4% compared to the same quarter last year. Research analysts forecast that Becton, Dickinson and Company will post 12.81 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 30th. Investors of record on Wednesday, June 9th were given a dividend of $0.83 per share. The ex-dividend date of this dividend was Tuesday, June 8th. This represents a $3.32 dividend on an annualized basis and a yield of 1.35%. Becton, Dickinson and’s dividend payout ratio is currently 32.55%.
Becton, Dickinson and Company Profile
Becton, Dickinson & Co is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.
Read More: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.